Myositis ossificans progressiva, multiple sites
ICD-10 M61.19 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, multiple sites.
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscles, tendons, and other connective tissues. This condition is caused by mutations in the ACVR1 gene, which plays a crucial role in bone and muscle development. Patients with MOP experience progressive muscle weakness and stiffness, often leading to significant functional impairment. The ossification typically occurs in multiple sites, including the neck, shoulders, back, and limbs, and can be triggered by trauma or may occur spontaneously. The condition is often misdiagnosed due to its rarity and the overlap of symptoms with other neuromuscular disorders. Diagnosis is primarily clinical, supported by imaging studies that reveal calcifications in soft tissues. Management focuses on symptomatic relief, physical therapy, and avoiding activities that may trigger ossification. Surgical intervention is generally avoided due to the risk of exacerbating the condition. Understanding the complexities of MOP is essential for accurate coding and effective patient management.
Detailed clinical notes on muscle weakness, stiffness, and any imaging studies performed.
Patients presenting with unexplained muscle pain and stiffness, particularly after minor trauma.
Ensure clear documentation of the progression of symptoms and any genetic testing results.
Genetic testing results and family history documentation.
Patients with a family history of myositis ossificans or unexplained ossification.
Document the specific genetic mutation identified and its implications for treatment.
Used for follow-up visits for management of myositis ossificans.
Detailed history and examination notes reflecting the patient's condition.
Rheumatology or genetics specialists should document the progression of symptoms and treatment plans.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues, leading to progressive muscle weakness and stiffness.
Diagnosis is primarily clinical, supported by imaging studies that reveal calcifications in soft tissues and confirmed by genetic testing for ACVR1 mutations.
